...
首页> 外文期刊>The journal of asthma >Macrophage migration inhibitory factor isolated from a parasite inhibited Th2 cytokine production in PBMCs of atopic asthma patients
【24h】

Macrophage migration inhibitory factor isolated from a parasite inhibited Th2 cytokine production in PBMCs of atopic asthma patients

机译:从寄生虫中分离出的巨噬细胞迁移抑制因子抑制了特应性哮喘患者PBMC中Th2细胞因子的产生

获取原文
获取原文并翻译 | 示例
           

摘要

Background. In a previous study, we demonstrated that the human macrophage migration inhibitory factor (MIF)-like protein (As-MIF) isolated from helminths could inhibit allergic airway inflammation via the recruitment of CD4 +CD25 +Foxp3 + T cells. Objective. To evaluate the clinical importance of As-MIF as an antiasthma drug, we evaluated immune responses after recombinant As-MIF (rAs-MIF) treatment in peripheral blood mononuclear cell (PBMC) cultures. Methods. PBMC was isolated from 10 patients with atopic asthma, 8 patients with nonatopic asthma, and 12 nonatopic healthy subjects, and various concentrations of rAs-MIF were transferred into the PBMC culture medium. After 3 days, we measured the levels of T helper 2 and T helper 1 cytokines via ELISA. Results. In atopic asthma, IL-4 and IL-5 production was significantly reduced in the PBMC cultures after rAs-MIF treatment. These inhibitory effects were not observed in the nonatopic asthma group. By way of contrast, IL-10 production in the PMBC cultures was significantly increased after rAs-MIF treatment in all experimental groups. Conclusion. The results of this study are similar to those previously reported in a mouse study, suggesting that As-MIF might be a candidate for the specific treatment of asthma.
机译:背景。在先前的研究中,我们证明了从蠕虫中分离出的人类巨噬细胞迁移抑制因子(MIF)样蛋白(As-MIF)可以通过募集CD4 + CD25 + Foxp3 + T细胞来抑制过敏性气道炎症。目的。为了评估As-MIF作为抗哮喘药物的临床重要性,我们评估了重组As-MIF(rAs-MIF)治疗后在外周血单核细胞(PBMC)培养物中的免疫应答。方法。从10名特应性哮喘患者,8名非特应性哮喘患者和12名非特应性健康受试者中分离出PBMC,并将各种浓度的rAs-MIF转移到PBMC培养基中。 3天后,我们通过ELISA测量了T辅助2和T辅助1细胞因子的水平。结果。在特应性哮喘中,rAs-MIF治疗后PBMC培养物中IL-4和IL-5的产生显着降低。在非特应性哮喘组中未观察到这些抑制作用。相比之下,在所有实验组中,rAs-MIF处理后,PMBC培养物中的IL-10产量均显着增加。结论。这项研究的结果与先前在小鼠研究中报道的结果相似,表明As-MIF可能是哮喘特异性治疗的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号